Kedzie Arrington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kedzie Arrington has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Cervantes
Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA
2 shared publications - Alan De la Rosa
Division of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, USA
1 shared publication - Andre Taylor
Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
1 shared publication - Bo-Young Hong
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
1 shared publication - Chin Griffin
Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
1 shared publication - Emily Bateman
Paul L Foster School of Medicine, 5001 El Paso Dr, El Paso, TX, 79905, USA
1 shared publication
Latest Publications
- Open Access
- 24 July 2024
- Published by MDPI AG in Microbiology Research
- Vol. 15 (3) , 1319-1325
IL-26 Increases Sensing of Borrelia burgdorferi DNA by Human Toll-like Receptor 9
Background: IL-26 has demonstrated antimicrobial properties, as well as in the degradation of DNA from the Lyme disease spirochete Borrelia burgdorferi (Bb). Additionally, IL-26 can promote macrophage activation and enhance Bb phagocytotic activity. It is unclear if cell-mediated immune responses are modulated through TLR9 signaling when exposed to IL-26 Bb DNA complexes in post-treatment Lyme disease syndrome (PTLDS). Objective: We here aim to explore the effect of IL-26 in human Toll-like receptor (TLR)-9’s activation upon the recognition of Bb DNA. Methods: We utilized a single-receptor cell system, HEK-Dual™ hTLR9 cells, which harbors two reporter plasmids for the NF-κB and IL-8 signaling pathways. Bb DNA was exposed to increasing concentrations of IL-26 in monomeric or dimeric form and then used to stimulate the cells for 4 h. The TLR-9 ligand CpG was used as a control. Results: We observed that NF-κB and IL-8 activation was maximal when the cells were stimulated with Bb DNA that had been treated with 5 µM of IL-26 monomer and 1 µM of IL-26 dimer. The same was observed for IL-8 activation upon CpG stimulation. We observed, however, a decrease in NF-κB activation when treated with either form of IL-26. An NF-κB activation increase did not occur with IL-26-treated TLR9 ligand CpG. Conclusions: Our study shows an enhancement in NF-κB and IL-8 activation upon the recognition of IL-26-treated Bb DNA by TLR9, which suggests an increase in sensing by the TLR9 of Bb DNA when it is in the form of an IL-26-Bb DNA complex. These findings will prompt further studies on the interaction between IL-26 and Bb DNA.
- 24 July 2024
- Published by MDPI AG in Microbiology Research
- Vol. 15 (3) , 1319-1325
Open AccessIL-26 Increases Sensing of Borrelia burgdorferi DNA by Human Toll-like Receptor 9
Background: IL-26 has demonstrated antimicrobial properties, as well as in the degradation of DNA from the Lyme disease spirochete Borrelia burgdorferi (Bb). Additionally, IL-26 can promote macrophage activation and enhance Bb phagocytotic activity. It is unclear if cell-mediated immune responses are modulated through TLR9 signaling when exposed to IL-26 Bb DNA complexes in post-treatment Lyme disease syndrome (PTLDS). Objective: We here aim to explore the effect of IL-26 in human Toll-like receptor (TLR)-9’s activation upon the recognition of Bb DNA. Methods: We utilized a single-receptor cell system, HEK-Dual™ hTLR9 cells, which harbors two reporter plasmids for the NF-κB and IL-8 signaling pathways. Bb DNA was exposed to increasing concentrations of IL-26 in monomeric or dimeric form and then used to stimulate the cells for 4 h. The TLR-9 ligand CpG was used as a control. Results: We observed that NF-κB and IL-8 activation was maximal when the cells were stimulated with Bb DNA that had been treated with 5 µM of IL-26 monomer and 1 µM of IL-26 dimer. The same was observed for IL-8 activation upon CpG stimulation. We observed, however, a decrease in NF-κB activation when treated with either form of IL-26. An NF-κB activation increase did not occur with IL-26-treated TLR9 ligand CpG. Conclusions: Our study shows an enhancement in NF-κB and IL-8 activation upon the recognition of IL-26-treated Bb DNA by TLR9, which suggests an increase in sensing by the TLR9 of Bb DNA when it is in the form of an IL-26-Bb DNA complex. These findings will prompt further studies on the interaction between IL-26 and Bb DNA.
- 1 April 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (5) , 443-450
Polypill Strategy in Secondary Cardiovascular Prevention
Purpose of Review The polypill strategy, originally developed to improve medication adherence, has demonstrated efficacy in improving baseline systolic blood pressures and cholesterol levels in multiple clinical trials. However, the long-term clinical impact of improved major cardiovascular events (MACE) outcomes by the polypill remains uncertain. Recent Findings Recent trials with long-term follow-up, which included minority groups and people with low socioeconomic status, have shown non-inferiority with no difference in adverse effects rates for the secondary prevention of MACE. Summary Although the polypill strategy was initially introduced to improve adherence to guideline-directed medical therapy (GDMT) for cardiovascular complications, the strategy has surpassed standard medical treatment for secondary prevention of MACE outcomes. Studies also showed improved medication compliance in underserved populations.
- 1 April 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (5) , 443-450
Polypill Strategy in Secondary Cardiovascular Prevention
Purpose of Review The polypill strategy, originally developed to improve medication adherence, has demonstrated efficacy in improving baseline systolic blood pressures and cholesterol levels in multiple clinical trials. However, the long-term clinical impact of improved major cardiovascular events (MACE) outcomes by the polypill remains uncertain. Recent Findings Recent trials with long-term follow-up, which included minority groups and people with low socioeconomic status, have shown non-inferiority with no difference in adverse effects rates for the secondary prevention of MACE. Summary Although the polypill strategy was initially introduced to improve adherence to guideline-directed medical therapy (GDMT) for cardiovascular complications, the strategy has surpassed standard medical treatment for secondary prevention of MACE outcomes. Studies also showed improved medication compliance in underserved populations.
- Open Access
- 7 March 2022
- Published by MDPI AG in Infectious Disease Reports
- Vol. 14 (2) , 176-183
Examining the Efficacy of Antimicrobial Therapy in Preventing the Development of Postinfectious Glomerulonephritis: A Systematic Review and Meta-Analysis
Postinfectious glomerulonephritis (PIGN) is an immune-mediated acute glomerulonephritis classically seen weeks after infection with Streptococcus pyogenes, although other infectious etiologies have emerged. While it has become increasingly rare in industrialized regions, it continues to affect children in developing countries. There has been debate as to why incidence rates are declining, including the possibility of improved initial treatment of bacterial infections. The ability of antimicrobial therapy in preventing PIGN as infectious sequelae, however, has not been comprehensively assessed. As varying evidence from published studies exists, the objective of this meta-analysis is to determine if antimicrobial therapy utilized to treat an initial infection has an effect in reducing the development of PIGN in humans. EMBASE, MEDLINE, and CENTRAL were searched using a comprehensive terminology strategy. From an initial search that returned 337 publications, 9 articles were included for analysis. Eight studies showed an incidence of PIGN after antimicrobial use ranging from 0.05% to 10% with a mean standardized difference (MSD) of 0.03 (0.01–0.06). Three studies showed an occurrence of PIGN without antibiotic use ranging from 1% to 13% with an MSD of 0.06 (−0.09–0.21). Our findings suggest that antimicrobial treatment for the initial infection may help diminish the development of PIGN. Although Streptococcus pyogenes infections are generally treated aggressively to prevent rheumatic fever, these findings may help further support the early treatment of bacterial infections to prevent postinfectious sequelae, especially as we consider other infectious etiologies of PIGN antimicrobial resistance.
- 7 March 2022
- Published by MDPI AG in Infectious Disease Reports
- Vol. 14 (2) , 176-183
Open AccessExamining the Efficacy of Antimicrobial Therapy in Preventing the Development of Postinfectious Glomerulonephritis: A Systematic Review and Meta-Analysis
Postinfectious glomerulonephritis (PIGN) is an immune-mediated acute glomerulonephritis classically seen weeks after infection with Streptococcus pyogenes, although other infectious etiologies have emerged. While it has become increasingly rare in industrialized regions, it continues to affect children in developing countries. There has been debate as to why incidence rates are declining, including the possibility of improved initial treatment of bacterial infections. The ability of antimicrobial therapy in preventing PIGN as infectious sequelae, however, has not been comprehensively assessed. As varying evidence from published studies exists, the objective of this meta-analysis is to determine if antimicrobial therapy utilized to treat an initial infection has an effect in reducing the development of PIGN in humans. EMBASE, MEDLINE, and CENTRAL were searched using a comprehensive terminology strategy. From an initial search that returned 337 publications, 9 articles were included for analysis. Eight studies showed an incidence of PIGN after antimicrobial use ranging from 0.05% to 10% with a mean standardized difference (MSD) of 0.03 (0.01–0.06). Three studies showed an occurrence of PIGN without antibiotic use ranging from 1% to 13% with an MSD of 0.06 (−0.09–0.21). Our findings suggest that antimicrobial treatment for the initial infection may help diminish the development of PIGN. Although Streptococcus pyogenes infections are generally treated aggressively to prevent rheumatic fever, these findings may help further support the early treatment of bacterial infections to prevent postinfectious sequelae, especially as we consider other infectious etiologies of PIGN antimicrobial resistance.